Table 5.

The risk per injection for adverse events reported in the 12 months before and after treatment switch in the 384 eyes that switched treatments

Adverse event	12 months leading up to switch (total 2781 injections) (%)	12 months postswitch (total 2885 injections*) (%)
Haemorrhage reducing BCVA by >15 letters	0.11	0.03
Infectious endophthalmitis	0.00	0.03
Non-infectious endophthalmitis	0.00	0.00
Intraocular surgery	0.65	0.28
Retinal detachment	0.00	0.03
RPE tear	0.11	0.03

*The injection received at time of switch is included in this injection count.

BCVA, best-corrected visual acuity; RPE, retinal pigment epithelium.